GCIA
SLXNW

Gabelli & Co Investment Advisers’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio SLXNW Stock Details SLXNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$774 Hold
38,150
– – ﹤0.01% 296
2025
Q4 		$992 Hold
38,150
– – ﹤0.01% 277
2025
Q3 		$1.34K Hold
38,150
– – ﹤0.01% 270
2025
Q2 		$1.56K Hold
38,150
– – ﹤0.01% 258
2025
Q1 		$2.92K Buy
+38,150
New +$2.32K ﹤0.01% 239
2024
Q4 		– Sell
-38,150
Closed -$1.21K – 265
2024
Q3 		$1.21K Buy
+38,150
New +$2.21K ﹤0.01% 212

Other funds holding SLXNW

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.39% 1-Year Est. Return

Gabelli & Co Investment Advisers's SLXNW Position: Q1 2026 in Review

Gabelli & Co Investment Advisers held its Silexion Therapeutics Warrant (SLXNW) position steady in Q1 2026 at 38,150 shares worth $774. The position accounts for ﹤0.01% of the portfolio, ranked #296.

Gabelli & Co Investment Advisers first reported a position in SLXNW in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.92K in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q1 2026.

  • Gabelli & Co Investment Advisers held 38,150 shares of Silexion Therapeutics Warrant worth $774 as of Q1 2026.
  • Gabelli & Co Investment Advisers left its Silexion Therapeutics Warrant share count unchanged in Q1 2026.
  • Silexion Therapeutics Warrant made up ﹤0.01% of Gabelli & Co Investment Advisers's portfolio in Q1 2026, its #296 holding.
  • Gabelli & Co Investment Advisers first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 6 quarters since.
  • Gabelli & Co Investment Advisers's Silexion Therapeutics Warrant position peaked at $2.92K in Q1 2025.
  • 19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q1 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.